Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...

Add surgical tweaks to fix so-called "Ozempic face" to the list of top trending cosmetic procedures, as tallied by the ...

Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.

And considering the rising popularity of Ozempic and other weight loss drugs, that is bound to catch folks’ attention. Toss ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

We talk Ozempic, Wegovy and Mounjaro. A number of studies have shown the amazing weight loss potential of a new group of ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...